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ABSTRACT
Objective: Peripheral artery disease (PAD), a common manifestation of
atherosclerosis, is characterized by lower leg ischemia and myopathy in association
with leg dysfunction. Patients with PAD have impaired gait from the first step they take
with consistent defects in the movement around the ankle joint, especially in plantar
flexion. Our goal was to develop muscle strength profiles to better understand the
problems in motor control responsible for the walking impairment in patients with PAD.
Methods: Ninety-four claudicating PAD patients performed maximal isometric plantar
flexion contractions lasting 10 seconds in two conditions: pain free (patient is well rested
and has no claudication symptoms) and pain induced (patient has walked and has
claudication symptoms). Sixteen matched healthy controls performed the pain-free
condition only. Torque curves were analyzed for dependent variables of muscle strength
and motor control. Independent t-tests were used to compare variables between
groups, and dependent t-tests determined differences between conditions.
Results: Patients with PAD had significantly reduced peak torque and area under the
curve compared with controls. Measures of control differed between PAD conditions
only. Load rate and linear region duration were greater in the pain condition. Time to
peak torque was shorter in the pain condition.
Conclusions: This study conclusively demonstrates that the plantar flexor muscles of
the PAD patient at baseline and without pain are weaker in patients with PAD compared
with controls. With the onset of claudication pain, patients with PAD exhibit altered
muscle control strategies and further strength deficits are manifest compared to
baseline levels. The myopathy of PAD legs appears to have a central role in the
functional deterioration of the calf muscles, as it is evident both before and after onset of
ischemic pain. (J Vasc Surg 2017;66:178-86.)

Peripheral artery disease (PAD) is a prevalent vascular disease affecting 8.5
million people in the United States.1 The most common presentation of PAD is
intermittent claudication, a condition in which when the patient walks, the metabolic
demands of the lower limbs exceed the limited supply of blood, causing ischemia and

exercise-induced discomfort and pain in the exercising leg. Chronic lower limb ischemia
and ischemia-reperfusion introduce biochemical and histologic changes in the muscles
of the affected legs, producing the well-described myopathy of PAD.2-4 Involved in this
myopathy are dysfunctional mitochondria bioenergetics, increased oxidative damage,
and fiber type shifting from type II to type I.2-9 The myopathic changes are associated
with decreased quality of life,10 leg function,11,12 poor health outcomes, and mortality in
patients with PAD.12,13 Furthermore, the functional effects of the myopathy are most
clearly seen in the gait alterations14-22 that claudicating patients demonstrate from the
first step they take before they experience any exercise-induced ischemia or pain.1416,18,19
The altered gait profile found in PAD patients presents as decreased muscle
power contributions at the ankle, knee, and hip joints. Among these findings, the
compromised biomechanics at the ankle joint are the most consistent deficits seen in
patients with PAD compared with controls.15,18,21,22 These alterations include a lack of
controlling the downward, plantar flexion motion of the foot on heel strike, 19 decreased
ankle power generation during push-off,22 decreased plantar flexion impulse,16
decreased energy output during the push-off phase of gait,15 and altered ankle angle
variability.14 These findings equate to an overall reduced ability for patients with PAD to
propel themselves forward during the late stance phase of gait and are present from the
first step the patients take while they become exacerbated after the onset of
claudication pain. Thus, submaximal muscle performance, common in most functional
tasks such as gait, has been quantified in detail in patients with PAD. Previous
investigations have also shown that patients with PAD have significantly reduced
maximal lower extremity strength compared with controls,7,23-25 but limited work has
investigated muscle strength beyond measurement of peak maximal output. A peak
maximal lower extremity strength measurement represents one value in time and alone
provides limited insight to the sequence of functions and mechanics that correspond to
normal gait or the muscle contraction abilities as a whole in these patients.
Incorporating variables beyond peak maximal strength that reflect the collaboration
between muscle and nerve during a contraction, such as torque generated over time
and torque variability, may provide a better understanding of the motor control deficits at
the ankle contributing to gait dysfunction in these patients.
Our objective was to develop a detailed strength profile of the ankle plantar
flexors in patients with PAD before and after the onset of claudication pain and to
compare it with that of non-PAD controls. We hypothesized that patients with PAD have
decreased strength output and altered control of the plantar flexor muscles.

METHODS
Participants.
The study was approved by the Institutional Review Boards at the Veterans
Affairs Medical Center of Nebraska and Western Iowa and the University of Nebraska

Medical Center. Informed consent was obtained from all participants before data
collection.
PAD group.
Ninety-four claudicating patients who were evaluated and diagnosed with PAD in
the vascular surgery clinic of the two institutions were recruited (Table I). All patients
with PAD were screened and evaluated by one of two board-certified vascular
surgeons. Diagnosis of PAD was based on medical history, physical examination,
significantly decreased resting ankle-brachial index (#0.9), and computed or standard
arteriography. Symptomatic claudication in at least one lower extremity during walking
was required for inclusion. Exclusion criteria included ambulation-limiting cardiac,
pulmonary, neuromuscular, or musculoskeletal conditions; rest pain; and history of
previous revascularization.
Control group.
Sixteen controls of similar age and anthropometric characteristics were recruited
through convenience sampling in the community (Table II). Control subjects were
screened in a manner similar to subjects with PAD, were excluded for the same criteria,
and were required to have an ankle-brachial index >0.9 and no subjective or objective
ambulatory dysfunction.
Experimental procedure and data collection.
Muscle strength was examined through isometric dynamometry using a Biodex
(System 4.0; Biodex Medical Systems, Shirley, NY). Isometric contractions are a wellestablished and reliable technique that is better tolerated by patients compared with an
isokinetic measurement.25 All subjects were secured in the Biodex and were positioned
so that the ipsilateral thigh was braced and supported with a knee angle of 30 degrees,
which allowed maximum contribution of the gastrocnemius. 26 The ankle was positioned
at 90 degrees, allowing maximum torque recruitment at the ankle. To isolate the plantar
flexor muscles, the contralateral thigh, waist, and chest were secured. The ankle was
secured to the Biodex attachment with the axis of rotation of the dynamometer aligned
with the subjects’ malleoli.
All control subjects walked on a treadmill for 3 minutes as a warm-up. Patients
with PAD walked for a maximum of 3 minutes or less if pain forced them to stop and
then rested until they were free of pain. Before testing, subjects were allowed to perform
submaximal trial-repetitions to get comfortable with the Biodex. Patients with PAD
performed pain-free and pain-induced conditions. During each condition, two repetitions
of maximal plantar flexion contraction for a duration of 10 seconds 26 were performed on
the more diseased leg of PAD patients with bilateral disease or the symptomatic leg of
patients with unilateral disease. Two repetitions provide a more representative sample
than a single repetition and are well tolerated by the patients. Controls performed only
the pain-free condition with the dominant leg. Each subject was instructed to push as

quickly and as hard as possible throughout the entire repetition. During the pain-free
condition, patients and controls rested for 1 minute between each repetition. This rest
period served to prevent the onset of claudication pain in subjects with PAD and to limit
the effect of fatigue in controls. After performing two repetitions of plantar flexion in the
pain-free condition, subjects were unstrapped from the Biodex, concluding the testing
for controls. Subjects with PAD were tested again in the pain condition, after
claudication pain was induced by walking on a treadmill at 2 mph and a 10% incline until
the subject reached a moderate level of pain that persisted. Immediately, subjects again
performed two maximal contractions of plantar flexion for 10 seconds each but were
given only 5 seconds of rest between repetitions.

Data analysis.
Each isometric plantar flexion was collected at 100 Hz in the Biodex, and the
resultant torque time series was imported into MATLAB (MathWorks, Natick, Mass) to
calculate dependent variables from custom scripts (Supplementary Figs 1-3, online
only). The linear region of each torque curve was identified for a more detailed analysis
of torque control during the maximal contraction. The linear region was determined as
the region in the torque curve that showed a trend of constant slope. Collectively, these
dependent variables provide a clear picture about the ability to control force output
during muscle contractions (Fig 1):

1. Area under the curve: total area under the torque curve. This measure is
representative of work performed during the contraction.
2. Peak torque: average torque produced during the linear region of the
contraction.
3. Time to peak torque: amount of time it takes to reach the start of the linear
region. This measure indicates the functional ability of the muscle to produce and
to maintain maximal torque quickly.
4. Linear region duration: amount of time during the contraction that the linear
region is maintained. This timing measure is representative of fatigue during
maximum contraction.
5. Standard deviation during the linear region: calculated during the defined
linear region to create a measure of variability. This represents an ability to
control a constant muscle contraction.
6. Load rate: the rate of torque applied during the first second of the contraction.
This timing measure indicates the ability to produce torque rapidly and is
indicative of muscle power.

Statistical analysis.
Means and standard deviations for each variable were calculated. Two
independent t-tests were used to compare PAD conditions independently with controls,
and one dependent t-test was used to compare PAD pain free vs PAD pain. A repeatedmeasures analysis of variance was used to perform linear trend analysis. Statistical
comparisons were performed using SPSS 22.0 software (IBM Corp, Armonk, NY), and
the significance level was set at .05.

RESULTS
Group means for age (P ¼ .49), body mass (P ¼ .57), and height (P ¼ .23) were
not different between patients with PAD and controls, verifying that the groups were well
matched (Table II).
In comparisons of PAD with controls, both peak torque and area under the curve
are greater in controls than in PAD pain-free and pain conditions (Table III, Fig 2). No
other variables were statistically different between both PAD conditions and the control
group.
Five variables were significant in comparisons between PAD pain-free and PAD
pain conditions (Table III, Fig 2). Peak torque, area under the curve, and time to peak
torque are all greater in the PAD pain-free condition. Load rate is larger and the linear
region is longer in the PAD pain condition. Thus, exercise-induced ischemic pain further
reduced strength and changed motor control in the plantar flexors of patients with PAD.
Standard deviation during the linear region yielded no significant comparisons.
The linear region of each torque curve was divided into three equal tertile regions for
further analysis. Trend analysis revealed a decreasing linear trend for torque variability
about the linear region, from beginning to end, in PAD conditions only (Table IV).

DISCUSSION
The purpose of this study was to create a more detailed strength profile of the
ankle plantar flexors to gain insight into the contribution of the ankle to the identified gait
abnormalities in patients with PAD.14-22 Measures of maximal strength and motor control
were measured while subjects performed isometric ankle plantar flexions with and
without claudication pain and were compared with controls. Our findings support our
hypothesis that significant differences exist in muscle strength profiles between controls
and patients with PAD. As expected, previously reported findings for reduced ground
reaction forces and joint powers15,16,18 coincide with the significant differences found for
area under the curve and peak torque of the plantar flexors in all comparisons.
Specifically, patients with PAD exhibited reduced area under the curve and peak torque
production compared with controls. The strength differences between controls and PAD
when subjects perform a 10-second isometric test immediately after rest and before any
exercise-induced ischemia/pain confirm that the weakness in the PAD ankle plantar
flexors is related to the well-described myopathy of PAD.2,4,9,11,27,28 Furthermore, the
introduction of ischemic claudication symptoms altered the motor control strategies of
the ankle plantar flexors, producing significant differences between PAD conditions.

Our data demonstrate that the plantar flexor muscles of PAD patients have
significant functional deficits. These deficits appear related to the neuropathy and
myopathy previously described by our group2-4,11,27,28 and others.5,6,29-31 Our work
demonstrates that there are functional tests, including the maximal isometric plantar
flexion test we are describing in this paper, that can measure and stratify the degree of
impairment in the legs of patients with PAD. Such measurements can be used as
diagnostic tools to assess the severity of PAD in each individual patient but also
potentially to predict and guide therapy, depending on the patient’s presentation. Our
group is currently evaluating multiple parameters of this myopathy as predictors of
outcomes after standard therapies (revascularization or supervised exercise) but also in

an effort to understand whether therapeutic measures can improve these deficits and to
what extent.
Decreased area under the curve.
Area under the curve is a measure of angular impulse during a contraction and is
indicative of work; the smaller area found in patients with PAD indicates that they are
unable to reach or to maintain a similar level of torque output during the same amount
of time as controls. Our results show a decreased total area in PAD torque curves at the
ankle plantar flexors and a decreased capacity to complete the same amount of work as
controls. The difference between controls and patients with PAD in pain-free conditions
was exacerbated in pain conditions.
Decreased peak torque.
Similarly, peak torque is highest in controls and lowest in the PAD pain condition.
Our results demonstrate a true deficit in strength at the ankle plantar flexors in patients
with PAD before the onset of pain. These findings further document the strength
decreases associated with PAD that could potentially contribute to gait deficits during
intermittent claudication by reducing total propulsive forces during push-off.
Works from other groups are in agreement with our finding of reduced strength in
the plantar flexor muscles of patients with PAD.7,12,24 Gerdle et al24 found that
patients with PAD produced lower peak torque and less contractile work than controls
during submaximal endurance testing of the plantar flexors.24 The methodology was
different in the study of Gerdle et al24; subjects performed a set of 30 nonfatiguing
isokinetic contractions at 180 degrees/s and a set of 200 fatiguing isokinetic
contractions at 60 degrees/s.24 Other work by Regensteiner et al7 showed reduced
levels of strength in the plantar flexors in patients with PAD that correlated with total calf
cross-sectional area and type II fiber cross-sectional area.7 Strength testing in the study
of Regensteiner et al7 was performed during two sets of five maximal-effort isokinetic
contractions at 60 degrees/s in pain-free conditions. The single highest torque for the
gastrocnemius and anterior tibial muscles was used for analysis.7 However, in a similar
study, Scott-Okafor et al25 tested strength at the ankle, knee, and hip but found
differences only at the dorsiflexors compared with individuals without PAD.25 Similar to
this study, Scott-Okafor et al25 used isometric testing but tested plantar flexor strength
with the knee at a 90-degree angle, whereas Regensteiner et al7 tested the ankle with
the knee fully extended and this study tested the ankle with slight flexion of 30 degrees
at the knee. The gastrocnemius crosses both the knee and the ankle joint; therefore, for
a given ankle plantar flexion torque, the contribution of the gastrocnemius is dependent
on the position of the knee. A more flexed knee decreases the overall plantar flexion
torque output by minimizing the contribution of the gastrocnemius, the main contributor
in plantar flexor contractions,32 and is likely the main reason that Scott-Okafor et al25
were not able to see the decrease in torque during plantar flexion. Collectively,

decreased strength about the ankle in patients with PAD is a common finding, and this
study adds to that conclusion.
Measures of motor control at plantar flexors.
To our knowledge, this is the first study to investigate muscle strength beyond a
measurement of the peak maximal force in patients with PAD. Measures of rate,
standard deviation, and timing (including time to peak torque, standard deviation during
linear region, linear region duration, and load rate) represent muscle motor control
because they assess the ability of a subject to produce a maximal contraction and detail
changes in the quality of the contraction during the course of the trial. The differences
found in these measures were only in comparisons between PAD conditions. Our data
did not demonstrate differences between PAD patients and controls.
Increased load rate in pain conditions.
A larger load rate indicates rapid torque production during the first second of the
isometric contraction. A steeper slope during the first second of contraction would
represent this on the torque curve. Load rate increased in pain conditions for PAD,
indicating that the onset of pain altered the initial approach to the contraction to perform
more work. It appears that induction of pain produces motor adjustments that lead to the
observed faster load rates. It is possible that pain input from sensory endings may
change the motor output into the symptomatic muscle, leading to increased recruitment
of motor units during the first second of the contraction. Another possibility is that once
symptoms have been induced, the neuromuscular system is sensitized and responds
quicker to the nerve impulses for contraction. Irrespective of the underlying mechanism,
the capacity of the myopathic tissues to perform more work is not maintained
throughout the contraction because our data demonstrated decreased overall area
under the curve in pain conditions.
Time to peak torque.
Time to peak torque was measured to assess whether timing differences existed
in maximal torque generation in an isometric contraction. PAD pain reached peak
torque quicker than in pain-free conditions, which is likely associated with the
concurrent decrease in peak torque observed in the pain condition. Specifically, the
PAD patients more quickly reach the level of peak torque while in pain because the
peak torque is lower than in the pain-free condition and they are able to arrive faster to
it. Although a quicker response may be the product of a neuromuscular system that is
more sensitive to nerve impulses, when it is combined with the finding of lower peak
torque and area under the curve, it indicates that the presence of symptoms
exacerbates the deficit in torque output capabilities in patients with PAD.
Linear region duration and standard deviation.
Linear region duration was significantly longer in the PAD pain condition
compared with baseline. It appears that because torque generation is of a lower

magnitude in the pain condition, the patients spend more time trying to maintain their
torque output because of an inability to generate more.
Standard deviation of the entire linear region elicited no significant comparisons.
Because of the large variance within this variable, we investigated variability in
maintenance of torque further by dividing the linear region of each curve into three
equal tertiles. Linear trend analysis revealed that variability about the linear region
decreased in PAD and did not change in controls. Neuro-muscular fatigue is known to
affect motor output during an isometric contraction by increasing the amount of
variability as a contraction progresses.33 Controls exhibit no trend because a healthy
neuromuscular interaction involves recruitment of more motor units to maintain torque
within a 10-second contraction, whereas the decreasing variability in PAD is an example
of less activity within the muscle. Myopathic fiber type shifting from type II to type I 2,9
and the neuropathy in PAD muscle that has been shown to decrease conduction
velocities and amplitude corroborate this trend. 29-31
Possible mechanisms for the strength and motor control deficits at the ankle.
This study confirmed the significant deficits in strength that have been found in
the ankle plantar flexors of patients with PAD previously. 7,15,16,21,22,25 During gait, the leg
of a patient with PAD is unable to generate normal power and to produce normal
positive work for push-off, indicated by reduced ankle plantar flexion torque and power
compared with adults without PAD.7,15,16,18 This gait deficit is present both before and
after the onset of claudication pain.16 Patients with PAD also have a reduced ability to
produce work during walking, independent of walking speed. 15 The deficits in strength
and ability to produce work with the plantar flexor muscles are likely key contributors to
the gait deficits that have been documented in patients with PAD.
Our findings are the result of maximal isometric strength assessments, which are
independent of blood flow, and demonstrate that deficits in patients with PAD relative to
controls reflect the metabolic myopathy and neuropathy that are present in the muscles
of patients with PAD.2,4,5 The effects of neuropathy in patients with PAD have been
found to include decreased nerve conduction velocities and decreased amplitude and
increased duration of motor unit action potential. 29-31 The myopathy in patients with PAD
involves defective mitochondrial bioenergetics, oxidative damage, myofiber
degeneration, and fibrosis of the affected skeletal muscles. 2-6,11,27,28,34,35 Increased
oxidative damage in PAD muscle is associated with deterioration of the size and shape
of myofibers in the gastrocnemius with preference for type II myofibers, whereas type I
fibers persist and are less damaged.9 Type II fibers are high-energy consumers and are
used in short explosive movements, such as the isometric contraction.36 The change in
myofiber type in the gastrocnemius in connection with defective mitochondria and
neuropathy demonstrates possible underlying mechanisms for the deficits we are
demonstrating in maximal torque generation and performance of effective work at the
plantar flexor muscles in patients with PAD relative to controls. It is evident from our
data that the onset of claudication pain affects motor control at the ankle in patients with

PAD. It is probable that during exercise-induced ischemia, fatigue, pain, and an
increased workload from restricted bioenergetics would alter the control of a muscle
contraction, especially at a maximal intensity for 10 seconds. To our knowledge, no
work with similar measures of motor control in the ankle plantar flexors currently exists
to compare our results with other populations and pathologic processes.
The parameters we have described allow quantitation of the degree of
neuromuscular impairment present in the legs of claudicating patients. These
parameters delineate the collaboration between muscle and nerve during leg
contraction and allow an objective assessment of the neuromuscular health of the leg of
each patient at baseline and the way it responds to different treatment modalities. If a
patient improves walking distances after treatment, knowledge of whether the
improvement is or is not reflected in muscle strength and performance can help us
understand how treatments raffect the performance of different muscle groups. Of
particular interest would be the possibility that after treatment, a patient increases the
ability to walk either without a measurable change (or even deterioration) in the
performance of the neuromuscular system or with a measurable improvement of certain
“unexpected” muscle groups. Based on these examples, it becomes obvious that there
are many and exciting opportunities for expanding our understanding of the
pathophysiologic mechanisms involved in PAD but also for taking advantage of these
mechanisms to modify current treatments and to propose new ones.
Control group size and the use of an isometric measurement instead of isokinetic
are possible limitations of this study. Isokinetic testing is more reflective of function
because strength is measured through a range of motion rather than in a static position.
However, the differences reported here provide insight into the functional capacity of the
muscle. Furthermore, an isometric test was tolerable for our patients in the pain
condition and still allowed measurement of the changes that occur because of pain.

CONCLUSIONS
Our findings conclusively confirm that the plantar flexor muscles of the PAD
patient have a significant functional impairment compared with controls. Impairments in
strength were present at baseline, providing more evidence for the impact of myopathy
and neuropathy of PAD on the skeletal muscle of claudicating patients. With the onset
of claudication pain, patients with PAD have further decrease in peak strength and
altered muscle control strategies at the ankle compared with base-line levels. The ankle
joint is of primary importance to proper gait mechanics and patterns, especially during
the push-off phase in late stance, and thus the deficits we describe have important
clinical implications for restoring function. Future biomechanics research in PAD
populations should examine the use of strength deficits as predictors of surgical and
exercise outcomes.
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